CiRA, Kyoto University and Astellas Phase 2 research agreement signed for iPS Cells
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Bourgoin early development hub broadens offerings for oral solid dose formulations
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
The event witnessed a historic journey of Thalassemics India gracing the theme “LAKSH”
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Subscribe To Our Newsletter & Stay Updated